Progyny Adds New Directors, Updates Executive Compensation
Ticker: PGNY · Form: 8-K · Filed: Jan 16, 2025 · CIK: 1551306
| Field | Detail |
|---|---|
| Company | Progyny, Inc. (PGNY) |
| Form Type | 8-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $40,000, $338,587, $139,750 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: PGNY
TL;DR
Progyny adds 2 new directors, Dr. David S. Chen & Ms. Karen L. Koster, effective Jan 10, 2025. Executive comp details updated.
AI Summary
On January 10, 2025, Progyny, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the company announced the election of two new directors, Dr. David S. Chen and Ms. Karen L. Koster, to its Board of Directors, effective January 10, 2025. The filing also disclosed updates to the compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine board and compensation changes, with no immediate financial distress or significant operational shifts indicated.
Key Players & Entities
- Progyny, Inc. (company) — Registrant
- Dr. David S. Chen (person) — Newly elected director
- Ms. Karen L. Koster (person) — Newly elected director
- January 10, 2025 (date) — Effective date of director elections
FAQ
Who are the newly elected directors to Progyny's Board?
Dr. David S. Chen and Ms. Karen L. Koster were elected to Progyny's Board of Directors.
When were the new directors elected?
The election of the new directors was effective as of January 10, 2025.
What other information is disclosed in this 8-K filing?
The filing also pertains to compensatory arrangements of certain officers.
What is Progyny, Inc.'s state of incorporation?
Progyny, Inc. is incorporated in Delaware.
What is Progyny's principal executive office address?
Progyny's principal executive offices are located at 1359 Broadway, New York, New York 10018.
Filing Stats: 958 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2025-01-16 09:24:49
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value per share PGNY The Nasdaq Gl
- $40,000 — he "Policy"), Ms. Morris will receive a $40,000 annual cash retainer for her service on
- $338,587 — ) an option grant in an amount equal to $338,587 to purchase shares of the Company's com
- $139,750 — icted stock units in an amount equal to $139,750, each of which will be granted on the d
Filing Documents
- pgny-20250110.htm (8-K) — 28KB
- 0001551306-25-000010.txt ( ) — 149KB
- pgny-20250110.xsd (EX-101.SCH) — 2KB
- pgny-20250110_lab.xml (EX-101.LAB) — 21KB
- pgny-20250110_pre.xml (EX-101.PRE) — 12KB
- pgny-20250110_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Progyny, Inc. Dated: January 16, 2025 By: /s/ Peter Anevski Peter Anevski Chief Executive Officer